A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple-Dose Subcutaneous Administration of MEDI-563, a Humanized Anti-Interleukin-5 Receptor Alpha Monoclonal Antibody, in Adults With Asthma.
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2016
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors MedImmune
- 08 Jan 2016 Pooled analysis of 2 trials including 24 patients from this study and another study (see CTP700033389) were published in the Respiratory Medicine.
- 25 Aug 2014 Planned number of patients changed from 24 to 25.
- 04 May 2012 Actual patient number is 25 as reported by ClinicalTrials.gov.